Published in J Clin Oncol on July 01, 1998
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet (2005) 4.98
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet (2004) 2.40
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol (2010) 1.89
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol (2009) 1.33
Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer (2007) 1.30
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res (2009) 1.22
Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat (2006) 1.20
Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology (2009) 1.17
Functional assays for BRCA1 and BRCA2. Int J Biochem Cell Biol (2006) 1.15
Breast cancer risk-assessment models. Breast Cancer Res (2007) 1.09
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood (2005) 1.09
Do-it-yourself genetic testing. Genome Biol (2010) 1.06
An analysis of unclassified missense substitutions in human BRCA1. Fam Cancer (2006) 1.04
The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer (2005) 1.00
Founder populations and their uses for breast cancer genetics. Breast Cancer Res (2000) 0.99
Hereditary breast cancer in Jews. Fam Cancer (2004) 0.99
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2000) 0.98
Predictors of cognitive appraisals following genetic testing for BRCA1 and BRCA2 mutations. J Behav Med (2004) 0.96
Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer (2007) 0.95
Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City. Public Health Genomics (2011) 0.94
Association between temporal orientation and attitudes about BRCA1/2 testing among women of African descent with family histories of breast cancer. Patient Educ Couns (2008) 0.92
Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol (2009) 0.91
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. Fam Cancer (2010) 0.90
The influence of acculturation and breast cancer-specific distress on perceived barriers to genetic testing for breast cancer among women of African descent. Psychooncology (2009) 0.90
Identification of women with an increased risk of developing radiation-induced breast cancer. Breast Cancer Res (2007) 0.88
BRCA1 Circos: a visualisation resource for functional analysis of missense variants. J Med Genet (2015) 0.88
BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res (2000) 0.88
An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population. Mol Diagn Ther (2014) 0.88
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland. Br J Cancer (2003) 0.88
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer (2004) 0.87
Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem (2007) 0.87
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86
Pharmacogenetics and personal genomes. Per Med (2009) 0.86
Reading between the lines: direct-to-consumer advertising of genetic testing. Hastings Cent Rep (2001) 0.86
Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: a study of familial and early onset cases. Hum Genet (2003) 0.85
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Virchows Arch (2013) 0.84
Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. J Exp Clin Cancer Res (2009) 0.83
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer (2004) 0.83
Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. J Transl Med (2016) 0.82
Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med (2009) 0.82
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer (2015) 0.82
Frailty Models for Familial Risk with Application to Breast Cancer. J Am Stat Assoc (2013) 0.82
Completeness of pedigree and family cancer history for ovarian cancer patients. J Gynecol Oncol (2014) 0.82
Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1. PLoS One (2014) 0.81
Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res (2014) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Why should primary care physicians know about breast cancer genetics? West J Med (2001) 0.79
Assessing biases of information contained in pedigrees for the classification of BRCA-genetic variants: a study arising from the ENIGMA analytical working group. Hered Cancer Clin Pract (2016) 0.79
Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg (2000) 0.78
Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int J Oncol (2012) 0.78
Assessing and managing breast cancer risk: clinical tools for advising patients. MedGenMed (2004) 0.78
Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. Fam Cancer (2010) 0.77
Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India. J Cancer Res Clin Oncol (2007) 0.77
Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2. J Community Genet (2010) 0.77
Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study. Int J Biochem Mol Biol (2014) 0.76
The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology. Breast Cancer Res (1999) 0.76
Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer. Dis Markers (2016) 0.75
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. BMC Cancer (2009) 0.75
Replication study for the association of seven genome- GWAS-identified Loci with susceptibility to ovarian cancer in the Polish population. Pathol Oncol Res (2014) 0.75
Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient. Springerplus (2014) 0.75
Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer. Behav Med (2014) 0.75
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature (1983) 11.57
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell (1992) 6.03
A malaria model tested in the African savannah. Bull World Health Organ (1974) 5.74
A note on competing risks in survival data analysis. Br J Cancer (2004) 5.60
Methyl-directed repair of DNA base-pair mismatches in vitro. Proc Natl Acad Sci U S A (1983) 5.34
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med (1984) 5.02
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet (2005) 4.98
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Strand-specific mismatch correction in nuclear extracts of human and Drosophila melanogaster cell lines. Proc Natl Acad Sci U S A (1990) 4.33
Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med (1987) 4.12
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science (1993) 3.89
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med (1997) 3.84
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst (1972) 3.78
Accumulation of chlorpyrifos on residential surfaces and toys accessible to children. Environ Health Perspect (1998) 3.75
Assessing the risk of breast cancer. N Engl J Med (2000) 3.72
Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med (1995) 3.71
A New Influence on Chemically Induced Sarcomata. Science (1948) 3.54
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
THE LIQUEFACTION OF SPONTANEOUS TUMORS OF THE MAMMARY GLAND IN MICE BY HEPTYL ALDEHYDE. Science (1938) 3.34
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2001) 3.23
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab (2001) 3.16
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med (1996) 3.04
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet (1972) 2.99
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Repair of DNA base-pair mismatches in extracts of Escherichia coli. Cold Spring Harb Symp Quant Biol (1984) 2.96
Isolation and characterization of the Escherichia coli mutH gene product. J Biol Chem (1987) 2.94
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
Characterization of a 50-kDa polypeptide in cytoplasmic dynein preparations reveals a complex with p150GLUED and a novel actin. J Biol Chem (1993) 2.91
Roundtable: what is temperament? Four approaches. Child Dev (1987) 2.88
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
Escherichia coli mutY gene encodes an adenine glycosylase active on G-A mispairs. Proc Natl Acad Sci U S A (1989) 2.87
Social comparison affects reward-related brain activity in the human ventral striatum. Science (2007) 2.87
Expression of a high-affinity mechanism for acquisition of transferrin iron by Neisseria meningitidis. Infect Immun (1982) 2.85
Mismatch repair proteins MutS and MutL inhibit RecA-catalyzed strand transfer between diverged DNAs. Proc Natl Acad Sci U S A (1994) 2.84
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol (1999) 2.79
Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol (1993) 2.79
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77
The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med (1999) 2.76
Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae. Infect Immun (2001) 2.75
Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet (1998) 2.74
Germ-line msh6 mutations in colorectal cancer families. Cancer Res (1999) 2.68
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet (1994) 2.66
Gender disparities in tuberculosis: report from a rural DOTS programme in south India. Int J Tuberc Lung Dis (2004) 2.64
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA (2000) 2.58
THE TREATMENT OF SPONTANEOUS TUMORS IN DOGS BY THE INJECTION OF HEPTYL ALDEHYDE. Science (1938) 2.57
The health and social needs of physically handicapped young adults: are they being met by the statutory services? Dev Med Child Neurol Suppl (1985) 2.56
Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA (1993) 2.51
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA (1995) 2.50
The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med (1998) 2.46
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Primary care for survivors of breast cancer. N Engl J Med (2000) 2.39
Circular polarization in star-formation regions: implications for biomolecular homochirality. Science (1998) 2.38
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood (1994) 2.38
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Prospective family predictors of aggression toward female partners for at-risk young men. Dev Psychol (1998) 2.36
On the irreducibility of a Markov chain defined on a space of genotype configurations by a sampling scheme. Biometrics (1993) 2.35
Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis (2000) 2.35
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31